Those with chronic obstructive pulmonary disease (COPD) may be more likely to suffer from a heart attack or stroke following an acute exacerbation if they have a history or at risk of cardiovascular disease (CVD).
Those with chronic obstructive pulmonary disease (COPD) may be more likely to suffer from a heart attack or stroke following an acute exacerbation if they have a history or at risk of cardiovascular disease (CVD).
According to new research, within the 30-day period following an acute exacerbation, heart attack or stroke odds are 4 times as likely. This was determined through an analysis of data from the Study to Understand Mortality and MorbidITy (SUMMIT) trial. The trial included patients who were previous or current smokers, 40 to 80 years old, have CVD or at risk for CVD, have a forced expiratory volume in 1 second of 50% to 70% of predicted, and a forced vital capacity of below or equal to 70%.
The data analysis resulted in the researchers attempting to identify the best interventions to study for after a COPD exacerbation in those with CVD.
“One approach might be to study currently used cardiac medications, such as antiplatelet agents, statins and/or beta-blockers immediately following COPD exacerbations,” Ken M. Kunisaki, MD, MS, the lead study author and associate professor of medicine at the University of Minnesota and Minneapolis VA Health Care System, said in a statement. “Another approach might be to use experimental drugs that specifically reduce inflammation.”
Because no interventions have been discovered, Kunisaki recommends that patients who recently experienced a COPD exacerbation and are noticing heart attack symptoms should seek care immediately and contact their care providers.
“One theory for why this happens is that COPD triggers inflammation and that, in turn, leads to CVD,” Kunisaki said in a statement. “Because COPD exacerbations lead to particularly high levels of inflammation, we wondered if these exacerbations would be linked to higher rates of CVD events.”
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More